Combined US/CEUS score outperforms ACR TI-RADS for benign high-risk thyroid nodules

A combined ultrasound and contrast-enhanced ultrasound score identified benign ACR TI-RADS 4/5 thyroid nodules better than ACR TI-RADS alone in internal validation: AUC 0.872 vs 0.720, specificity 75.5% vs 55.1%, sensitivity 94.4% vs 88.9%. Single-center retrospective.

• In subgroup analysis, the US+CEUS score achieved 92.6% specificity in TR4 nodules and 96.9% sensitivity in TR5 nodules.
• When CEUS was unavailable, a US-only score achieved AUC 0.861, sensitivity 91.7%, and specificity 67.3%.
• The study used single-center internal split-sample validation; the authors state external validation in prospective, unselected populations is warranted before clinical implementation.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.